This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hande, K. R. Articles by Hainsworth, J. D. Search for Related Content PubMed PubMed Citation Articles by Hande, K. R. Articles by Hainsworth, J. D.

Kinetics of N-[(4-Chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in Humans¹

Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine [K. R. H., J. K., L. J., J. D. H.], Nashville, Tennessee 37232, and the Eli Lilly Company [M. H., W. S., G. G.], Indianapolis, Indiana 46285

The metabolism and disposition of LY186641, a diarylsulfonylurea with antineoplastic activity identified in preclinical tests, was determined in 21 patients who received 23 courses of orally administered drug. A linear correlation was found between the dose of drug administered and LY186641 peak plasma concentrations and LY186641 area under the curve measurements. Clearance (135 ± 36 ml/h/m²), terminal half-life (31 ± 11 h), and volume of distribution (10.2 ± 2.8 liters) were independent of drug dose. No LY186641 was excreted in urine. Hydroxy and keto metabolites of LY186641 were identified in plasma and urine samples. Urinary excretion of these metabolites during the initial 48 h following drug administration accounted for 20% of LY186641 disposition. Plasma half-life of the hydroxy and keto metabolites was longer than that of parent drug (3.3 and 3.1 days, respectively). Plasma concentrations of parent drug correlated with the presence of methemoglobinemia, the dose-limiting toxicity found with LY186641.

¹ Work supported in part by the Veterans Administration.

² To whom requests for reprints should be addressed, at Department of Medicine, Division of Oncology, Vanderbilt University, Nashville, TN 37232-5536.

Received 1/ 2/90. Revised 3/12/90.